Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG)

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Huiskens, Joost ^a   van Gulik, Thomas M ^a   van Lienden, Krijn P ^a   Engelbrecht, Marc R W ^a   Meijer, Gerrit A ^b   van Grieken, Nicole C T ^b   Schriek, Jonne ^c   Keijser, Astrid ^c   Mol, Linda ^c   Molenaar, I Quintus ^d   Verhoef, Cornelis ^e   de Jong, Koert P ^f   Dejong, Kees H C ^g   Kazemier, Geert ^b   Ruers, Theo M ^h   de Wilt, Johanus H W ⁱ   van Tinteren, Harm ^h   Punt, Cornelis J A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Netherlands Comprehensive Cancer Organisation   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ERASMUS MC CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Treatment strategies; Unresectable colorectal liver metastases

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FOLINIC ACID; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ARTICLE; CANCER SURGERY; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; ONCOGENE RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TRANSLATIONAL RESEARCH; ADULT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84938965788     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1323-9     Document Type: Article

References (31)

1. Van Gestel YRBM, de Hingh IHJT, van Herk-Sukel MPP, van Erning FN, Beerepoot LV, Wijsman JH, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38:448-54. Elsevier Ltd; 2014 Aug [cited 2014 Sep 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24841870.
2. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-83. 2009 Aug 1 [cited 2014 Mar 4]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2720081&tool=pmcentrez&rendertype=abstract.
3. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-20. Lippincott, Williams, and Wilkins; 1996 Oct 1 [cited 2014 Mar 12]; discussion 520-522. Available from: /pmc/articles/PMC1235414/?report=abstract.
4. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg. 2004;240:644-58. Lippincott, Williams, and Wilkins; 2004 Oct 1 [cited 2014 Feb 10]. Available from: /pmc/articles/PMC1356466/?report=abstract.
5. LiverMetSurvey. LiverMetSurvey [Internet]. 2014 [cited 2014 Mar 12]. Available from: http://www.livermetsurvey.org/.
6. Folprecht G, Gruenberger T, Bechstein WO, Raab H-R, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47. 2010 Jan [cited 2014 Jan 21]. Available from: https://c48xyy2mc98ffeali7cn5hdm.sec.amc.nl/science/article/pii/S1470204509703304.
7. Koopman M, Punt CJ. Chemotherapy, which drugs and when. Eur J Cancer. 2009;45 Suppl 1:50-6. Elsevier Ltd; 2009 Sep [cited 2014 Sep 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19775604.
8. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor. J Clin Oncol. 2007;25:1670-6. 2007 May 1 [cited 2014 Aug 23]. Available from: http://jco.ascopubs.org/content/25/13/1670.abstract.
9. Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103:21-30. Jan 5 [cited 2014 Sep 1]. Available from: http://jnci.oxfordjournals.org/content/103/1/21.abstract.
10. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog. Br J Cancer. 94:798-805. Cancer Research UK; 2006 Mar 27 [cited 2014 Mar 2]. Available from: http://dx.doi.org/10.1038/sj.bjc.6603011.
11. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-5. Available from: http://jco.ascopubs.org/content/26/11/1830.abstract.
12. Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer. 2011;104:1079-84. Available from: https://www.pubchase.com/article/21386839.
13. Heinemann V, Weikersthal L von. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German. ASCO 2013 Abstr. 2013. [cited 2014 Mar 12]; Available from: http://meeting.ascopubs.org/cgi/content/abstract/31/18_suppl/LBA3506.
14. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon J-L, Hecht JR, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal. J Clin Oncol. 2014;32:2240-7. 2014 Jul 20 [cited 2014 Jul 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24687833.
15. Venook AP, Niedzwiecki D, Lenz H, Innocenti F, Mahoney MR, Bert H, et al. Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5- FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). ASCO 2014 Abstr LBA3.
16. Falcone A, Cremolini C, Masi G. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. ASCO 2013 Abstr 3505. [cited 2014 Mar 13]; Available from: http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3505
17. Chun YS, Vauthey J-N, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338-44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19952320.
18. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30:4566-72. 2012 Dec 20 [cited 2014 Mar 25]. Available from: http://jco.ascopubs.org/content/30/36/4566.abstract.
19. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32:437-53. Excerpta Medica Inc.; 2010 Mar [cited 2014 Jul 22]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20399983.
20. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377:2103-14. 2011 Jun 18 [cited 2014 Feb 28]. Available from: https://c48xyy2mc98ffeali7cn5hdm.sec.amc.nl/science/article/pii/S0140673611606132.
21. Lièvre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-5. 2006 Apr 15 [cited 2014 Jul 10]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16618717.
22. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-62. Available from: https://www.pubchase.com/article/20619739.
23. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023-34. [cited 2014 Jul 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24024839.
24. Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361:98-9. Massachusetts Medical Society; 2009 Jul 2. Available from: http://dx.doi.org/10.1056/NEJMc0904160.
25. Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-9. 2011 May 20 [cited 2014 Feb 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21502544.
26. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15:569-79. Elsevier Ltd; 2014 May [cited 2014 Jul 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24739896
27. TSACP MiSeq analysis. 2014. www.Illumina.com.
28. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11-6. 2011 Jan 1 [cited 2014 Jul 21]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3055856&tool=pmcentrez&rendertype=abstract.
29. De Gramont A, Van Cutsem E, Schmoll H-J, Tabernero J, Clarke S, Moore MJ. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225-33. Elsevier Ltd; 2012 Dec [cited 2014 Jul 22]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23168362.
30. Alberts SR, Sargent DJ, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer a randomized trial. JAMA. 2012;307:1383-93.
31. Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601-11. 2014 May [cited 2014 May 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24717919.